A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg QD When Added to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Inhibitor Therapy
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Bempedoic acid (Primary) ; Evolocumab
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Esperion Therapeutics
- 27 Mar 2018 Results presented in an Esperion Therapeutics Media Release.
- 27 Mar 2018 According to an Esperion Therapeutics media release, primary endpoint (Percent change of low-density lipoprotein cholesterol (LDL-C)) has been met.
- 26 Feb 2018 Status changed from active, no longer recruiting to completed.